Small molecules targeting the GLI transcription factors, defined as GLI antagonists, are an emerging cancer therapy currently under investigation in preclinical studies and might be effective in tumors with canonical and non-canonical activation of HH pathway [106]. This evidence concerns the gene GLI1 and cancer.